Choosing the best path to patients: how to decide between in-house and outsourced iPSC therapy development and manufacturing
Year: 2025
Type: article
Abstract: Induced pluripotent stem cells (iPSCs) offer the potential of creating life-changing regenerative medicine products for many current unmet needs. To ensure iPSC-based therapies have the possibility to reach their breakthroughs potential, we as developers should ensure that they actually can be accessible to patients—and that means considering also the market demands of the over-burdened healthcare systems across the world. In this article, we offer some viewpoints and considerations around the accessibility of therapies from the cost perspective, debating the alternative models of development and manufacturing of iPSC-based therapies.
Source: Cell and Gene Therapy Insights
Authors: Laura Koivusalo, Anni Mörö, Ross Macdonald
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W7115173179
FWCI:
Cites:
Cited by:
Related to: